3.600SEK-1.64%Mkt Cap: 381.97M SEKP/E: 3.69Last update: 2026-05-13
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various typ…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)3.69
P/E (Forward)2.78
PEG—
P/B3.21
P/S2.28
EV/EBITDA2.59
EV/Revenue1.53
EPS (TTM)0.98
EPS (Forward)1.30
Cash Flow & Leverage
FCF Yield13.72%
FCF Margin31.31%
Operating CF83.53M SEK
CapEx (TTM)94.00K SEK
Net Debt/EBITDA-1.28
Net Debt-126.70M SEK
Technical
SMA 502.831 (+27.2%)
SMA 2001.556 (+131.3%)
Beta-0.52
S&P 52W Chg24.23%
Avg Vol (30d)913.08K
Avg Vol (10d)740.48K
Technical Indicators
RSI (14)59.1
MACD0.2558
MACD Signal0.2464
MACD Hist.+0.0093
BB Upper4.011 SEK
BB Middle3.376 SEK
BB Lower2.741 SEK
BB Width37.63%
ATR (14)0.3411 SEK
Vol Ratio (20d)0.85x
52W Range
0.360084% of range4.210
52W High4.210 SEK
52W Low0.3600 SEK
Profitability
Gross Margin92.18%
EBITDA Margin58.92%
Profit Margin54.88%
Oper. Margin87.81%
ROE76.97%
ROA67.13%
Revenue Growth699.90%
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio7.60
Quick Ratio7.60
Book Value/Sh1.129 SEK
Cash/Share1.201 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.105.52M
Float70.62M
Insiders35.22%
Institutions31.75%
Analyst Consensus
Rating—
Target (Mean)3.300 SEK
Target Range3.300 SEK – 3.300 SEK
# Analysts1
Company
Market Cap381.97M SEK
Enterprise Value255.26M SEK
Revenue (TTM)167.38M SEK
Gross Profit154.09M SEK
Net Income (TTM)91.74M SEK
Revenue/Share1.808 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees30
Last Price3.600 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0006343745